Ascentage Pharma Group International (AAPG) Liabilities and Shareholders Equity (2023 - 2026)

Ascentage Pharma Group International's Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $558.8 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 53.34% year-over-year to $558.8 million; the TTM figure through Dec 2025 stood at $1.7 billion (changed N/A YoY), while the FY2025 annual figure was $551.5 million, up 51.34% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $558.8 million, up from $425.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $558.8 million in Q4 2025, with the low at $347.3 million in Q4 2023.
• The 3-year median for Liabilities and Shareholders Equity is $394.8 million (2024), against an average of $423.9 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity increased 4.94% in 2024, then surged 53.34% in 2025.
• Ascentage Pharma Group International's Liabilities and Shareholders Equity stood at $347.3 million in 2023, then advanced by 4.94% to $364.4 million in 2024, then soared by 53.34% to $558.8 million in 2025.
• Business Quant data shows AAPG's Liabilities and Shareholders Equity at $558.8 million in Q4 2025, $425.2 million in Q2 2025, and $364.4 million in Q4 2024.